Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

Clinical Therapeutics

Volumn 30, Issue 5, 2008, Pages 974-985

  Farrar, John T ^a   Troxel, Andrea B ^a   Stott, Colin ^b   Duncombe, Paul ^b   Jensen, Mark P ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Porton Down Science Park   (United Kingdom)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

cannabinoids; measurement; numerical rating scale; spasticity

Indexed keywords

BACLOFEN; BENZODIAZEPINE DERIVATIVE; ENDOCANNABINOID; GABAPENTIN; TIZANIDINE;

ADULT; ARTICLE; ASHWORTH SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIPLE SCLEROSIS; NUMERIC RATING SCALE; PATIENT GLOBAL IMPRESSION OF CHANGE; POST HOC ANALYSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SPASM FREQUENCY SCALE; SPASTICITY; STATISTICAL SIGNIFICANCE; SYMPTOM; TEST RETEST RELIABILITY; VALIDITY;

FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS;

EID: 44849131341     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.05.011     Document Type: Article

References (46)

1. Sköld C., Levi R., and Seiger A. Spasticity after traumatic spinal cord injury: Nature, severity, and location. Arch Phys Med Rehabil 80 (1999) 1548-1557
2. Lance J. Pathophysiology of spasticity and clinical experience with baclofen. In: Lance J., Feldman R., Young R., and Koella W. (Eds). Spasticity: Disordered Motor Control (1980), Year Book, Chicago, Ill 185-204
3. Pandyan A., Gregoric M., Barnes M., et al. Spasticity: Clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 27 (2005) 2-6
4. Shakespeare D., Boggild M., and Young C. Antispasticity agents for multiple sclerosis (Cochrane Review). The Cochrane Library, Issue 2 (2004), John Wiley & Sons Ltd, Chichester, United Kingdom
5. Farrar J., Young Jr. J., LaMoreaux L., et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94 (2001) 149-158
6. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 192 (1964) 540-542
7. Pandyan A., Johnson G., Price C., et al. A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil 13 (1993) 373-383
8. Pandyan A., Price C., Barnes M., and Johnson G. A biomechanical investigation into the validity of the modified Ashworth Scale as a measure of elbow spasticity. Clin Rehabil 17 (2003) 290-293
9. Ansari N., Naghdi S., Moammeri H., and Jalaie S. Ashworth Scales are unreliable for the assessment of muscle spasticity. Physiother Theory Pract 22 (2006) 119-125
10. Nuyens G., De Weerdt W., and Ketelaer P. Interrater reliability of the Ashworth Scale in multiple sclerosis. Clin Rehabil 8 (1994) 286-292
11. Collin C., Davies P., Mutiboko I., and Ratcliffe S. for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 14 (2007) 290-296
12. Biering-Sørensen F., Nielsen J., and Klinge K. Spasticityassessment: A review. Spinal Cord 44 (2006) 708-722
13. Bland J., and Altman D. Statistics notes: Validating scales and indexes. BMJ 324 (2002) 606-607
14. Fleiss J. The Design and Analysis of Clinical Experiments (1986), John Wiley & Sons, New York, NY
15. Fleiss J., Levin B., and Paik M. Statistical Methods for Rates and Proportions. 3rd ed (2003), John Wiley & Sons, Hoboken, NJ
16. Jensen M., and McFarland C. Increasing the reliability and validity of pain intensity measurement in chronic pain patients. Pain 55 (1993) 195-203
17. Farrar J., Berlin J., and Strom B. Clinically important changes in acute pain outcome measures: A validation study. J Pain Symptom Manage 25 (2003) 406-411
18. Hanley J. Receiver operating characteristic (ROC) methodology: The state of the art. Crit Rev Diagn Imaging 29 (1989) 307-335
19. Jensen M., Turner J., Romano J., and Fisher L. Comparative reliability and validity of chronic pain intensity measures. Pain 83 (1999) 157-162
20. Pandyan A., Johnson G., Priec C., et al. A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil 13 (1999) 373-383
21. Sköld C. Spasticity in spinal cord injury: Self- and clinically rated intrinsic fluctuations and interventioninduced changes. Arch Phys Med Rehabil. 81 (2000) 144-149
22. Burridge J., Wood D., Hermens H., et al. Theoretical and methodological considerations in the measurement of spasticity. Disabil Rehabil 27 (2005) 69-80
23. Hsieh J., Wolfe D., Miller W., and Curt A. for the SCIRE Research Team. Spasticity outcome measures in spinal cord injury: Psychometric properties and clinical utility. Spinal Cord 46 (2008) 86-95
24. Platz T., Eickhof C., Nuyens G., and Vuadens P. Clinical scales for the assessment of spasticity, associated phenomenam and function: A systematic review of the literature. Disabil Rehabil 27 (2005) 7-18
25. Hobart J., and Thompson A. Measurement of neurological outcomes. In: Asbury A., McKhann G., McDonald W., et al. (Eds). Diseases of the Nervous System: Clinical Neuroscience and Therapeutic Principles. 3rd ed (2002), Cambridge University Press, Cambridge, UK 105-117
26. Turner-Stokes L. Measurement of outcome in rehabilitation: "Basket" of measures. British Society of Rehabilitation Medicine (2002), London, UK
27. Hobart J., Riazi A., Lamping D., et al. Improving the evaluation of therapeutic interventions in multiple sclerosis: Development of a patient-based measure of outcome. Health Technol Assess. 8 iii (2004) 1-48
28. Revicki D., Hays R., Cella D., and Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61 (2008) 102-109
29. Dworkin R., Turk D., Farrar J., et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113 (2005) 9-19
30. Dworkin R., Turk D., Wyrwich K., et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9 (2008) 105-121
31. Jensen M., and Karoly P. Self-report scales and procedures for assessing pain in adults. In: Turk D., and Melzack R. (Eds). The Handbook of Pain Assessment (1992), Guilford Press, New York, NY 135-151
32. Zajicek J., Fox P., Sanders H., et al., UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebocontrolled trial. Lancet 362 (2003) 1517-1526
33. Wade D., Robson P., House H., et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17 (2003) 21-29
34. Wade D., Makela P., Robson P., et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebocontrolled study on 160 patients. Mult Scler 10 (2004) 434-441
35. Killestein J., Hoogervorst E., Reif M., et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58 (2002) 1404-1407
36. Zajicek J., Sanders H., Wright D., et al. Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 76 (2005) 1664-1669
37. Wade D., Makela P., House H., et al. Long-term use of a cannabisbased medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 12 (2006) 639-645
38. Revicki D., Erickson P., Sloan J., et al. for the Mayo/FDA Patient- Reported Outcomes Consensus Meeting Group. Interpreting and reporting results based on patient reported outcomes. Value Health 10 Suppl 2 (2007) S116-S124
39. van Seventer R., Feister H., Young Jr. J., et al. randomized trial. Curr Med Res Opin 22 (2006) 375-384
40. Baron R., Brunnmüller U., Brasser M., et al. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study [published online ahead of print Jan 30, ]. Eur J Pain (2008) doi:10.1016/j.ejpain.2007.12. 004
41. Hobart J., Riazi A., Thompson A., et al. Getting the measure of spasticity in multiple sclerosis: The Multiple SclerosisSpasticityScale(MSSS-88). Brain 129 (2006) 224-234
42. Just N., Ciccone D., Bandilla E., and Wu W. Global impressions versus validated measures of treatment effectiveness in patients with chronic nonmalignant pain. Rehabil Psychol 44 (1999) 194-207
43. Jenkinson C., Peto V., and Coulter A. Measuring change over time: A comparison of results from a global single item of health status and the multidimensional SF-36 health status survey questionnaire in patients presenting with menorrhagia. Qual Life Res 3 (1994) 317-321
44. Juniper E., Guyatt G., Willan A., and Griffith L. Determining a minimal important change in a diseasespecific Quality of Life Questionnaire. J Clin Epidemiol. 47 (1994) 81-87
45. Buchbinder R., Bombardier C., Yeung M., and Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures' responsiveness to treatment in a randomized controlled trial. Arthritis Rheum 38 (1995) 1568-1580
46. Hurst H. Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther 27 (2004) 26-35